Rofecoxib Patent Expiration
Rofecoxib is Used for relieving symptoms of osteoarthritis, rheumatoid arthritis, acute pain, primary dysmenorrhea, and acute migraine attacks in adults. It was first introduced by Merck Research Laboratories Div Merck Co Inc
Rofecoxib Patents
Given below is the list of patents protecting Rofecoxib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vioxx |
US6063811 (Pediatric) | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov 06, 2017
(Expired) | Merck |
| Vioxx | US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May 06, 2017
(Expired) | Merck |
| Vioxx |
US5691374 (Pediatric) | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov 18, 2015
(Expired) | Merck |
| Vioxx | US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May 18, 2015
(Expired) | Merck |
| Vioxx |
US5474995 (Pediatric) | Phenyl heterocycles as cox-2 inhibitors |
Dec 24, 2013
(Expired) | Merck |
| Vioxx |
US6239173 (Pediatric) | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec 24, 2013
(Expired) | Merck |
| Vioxx | US5474995 | Phenyl heterocycles as cox-2 inhibitors |
Jun 24, 2013
(Expired) | Merck |
| Vioxx | US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun 24, 2013
(Expired) | Merck |
Rofecoxib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List